1384P DKN-01 in Combination with Tislelizumab and Chemotherapy As a First-Line Therapy in Unselected Patients with Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial

Dickkopf-1 (DKK1) modulates Wnt signaling and contributes to an immune suppressive tumor microenvironment. DKN-01 (D), a neutralizing DKK1 antibody, in combination with an anti-PD1 antibody, has demonstrated safety and clinical activity in advanced previously treated DKK1-high GEA. We report response and survival outcomes in GEA patients (pts) treated with D + tislelizumab (T) + capecitabine/oxaliplatin (CAPOX) as a first line therapy.